Can palliative radiotherapy influence prostate-specific antigen response in patients with castrate-resistant prostate cancer treated with systemic therapy (chemotherapy or abiraterone)?—a report of three cases

Mohan Hingorani; Sanjay Dixit; Pattu Pugazhenthi; Simon Hawkyard; Andrew Robertson; Richard Khafagy

doi:10.7497/j.issn.2095-3941.2014.0025

Article Information

vol. 12 no. 1 60-63

DOI

https://doi.org/10.7497/j.issn.2095-3941.2014.0025

PubMed

25859413

Published By

Cancer Biology & Medicine

History

Received November 26, 2015
Accepted January 22, 2015
Published online March 1, 2015.

Copyright: © 2015, Cancer Biology & Medicine https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY) 4.0, which permits unrestricted use, distribution and reproduction in any medium, provided the original author and source are credited.

Author Information

Mohan Hingorani⇑1,
Sanjay Dixit1,
Pattu Pugazhenthi1,
Simon Hawkyard2,
Andrew Robertson2 and
Richard Khafagy2

¹Department of Clinical Oncology, Castle Hill Hospital, Hull and East Yorkshire, NHS Trust, Cottingham, East Riding of Yorkshire, HU16 5JQ, UK
²Department of Urology, Scarborough District General Hospital, Scarborough ON M1P 2V5, UK